Published in Cancer Weekly, November 2nd, 2004
Interim results from this dose-escalation trial were reported by GenVec and presented at the European Organization for Research and Treatment of Cancer meeting in Geneva, Switzerland on October 1, 2004.
GenVec has provided additional data to the FDA and expects to receive a letter from the agency confirming the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.